Peddock Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Peddock Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-26	Closed	-$4K	–	272
2020 Q4	$4K	Buy	+26	New	+$3.85K	﹤0.01%	249
2020 Q1	–	Sell	-54	Closed	-$7K	–	217
2019 Q4	$7K	Buy	+54	New	+$5.45K	﹤0.01%	227
2019 Q2	–	Sell	-54	Closed	-$6K	–	214
2019 Q1	$6K	Hold	54	–	–	﹤0.01%	230
2018 Q4	$6K	Hold	54	–	–	﹤0.01%	232
2018 Q3	$9K	Hold	54	–	–	﹤0.01%	230
2018 Q2	$7K	Hold	54	–	–	﹤0.01%	231
2018 Q1	$4K	Hold	54	–	–	﹤0.01%	233
2017 Q4	$3K	Hold	54	–	–	﹤0.01%	238
2017 Q3	$2K	Hold	54	–	–	﹤0.01%	241
2017 Q2	$2K	Hold	54	–	–	﹤0.01%	243
2017 Q1	$2K	Hold	54	–	–	﹤0.01%	224
2016 Q4	$1K	Hold	54	–	–	﹤0.01%	225
2016 Q3	$3K	Buy	+54	New	+$1.63K	﹤0.01%	221

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Peddock Capital Advisors's SRPT Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 26 shares — an estimated $4K sold.

Peddock Capital Advisors first reported a position in SRPT in Q3 2016 and held it in 13 quarters. The position peaked at $9K in Q3 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Peddock Capital Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Peddock Capital Advisors sold 26 Sarepta Therapeutics shares in Q1 2021, an estimated $4K.
Peddock Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 13 quarters.
Peddock Capital Advisors's Sarepta Therapeutics position peaked at $9K in Q3 2018.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.